Products

View as  
 
Gemcitabinum hydrochloridum API

Gemcitabinum hydrochloridum API

Seres productum nomen: Gemcitabine HCl
Sinensis alias: Gemcitabine Hydrochloride; Gemcitabine HCl API; Gemcitabine Hydrochloride API; 4-amino-1-[3,3-difluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl] -1h-pyrimidin-2-one hydrochloride; Anti-tumor Gemcitabine
Anglicus productum nomen: Gemcitabinum hydrochloridum
CAS#122111-03-9

Lege plusMitte Inquisitionem
Gemcitabine HCl API

Gemcitabine HCl API

Seres productum nomen: Gemcitabine HCl
Sinensis alias: Gemcitabine Hydrochloride; Gemcitabine HCl API; Gemcitabine Hydrochloride API; 4-amino-1-[3,3-difluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl] -1h-pyrimidin-2-one hydrochloride; Anti-tumor Gemcitabine
Anglicus productum nomen: Gemcitabinum hydrochloridum
CAS#122111-03-9

Lege plusMitte Inquisitionem
Gemcitabinum hydrochloridum

Gemcitabinum hydrochloridum

Seres productum nomen: Gemcitabine HCl
Sinensis alias: Gemcitabine Hydrochloride; Gemcitabine HCl API; Gemcitabine Hydrochloride API; 4-amino-1-[3,3-difluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl] -1h-pyrimidin-2-one hydrochloride; Anti-tumor Gemcitabine
Anglicus productum nomen: Gemcitabinum hydrochloridum
CAS#122111-03-9

Lege plusMitte Inquisitionem
CAS#169590-42-5

CAS#169590-42-5

CAS#169590-42-5 est pro medicamento nonsteroidali anti-inflammatorio, pro medicamento OSTEOARTHRITIS, ARTHRITIS ARTHRITIS MEDICO, ARTHRITIS ARTHRITIS rheumatoidei juvenili medicamento.

Lege plusMitte Inquisitionem
CAS#540737-29-9

CAS#540737-29-9

CAS#540737-29-9 est medicamento arthritis rheumatoidei, arthritis psoriatica medicamentum, spondylitis medicamentum ankylosingum, polyarticularis utique pharmacum arthritis juvenile idiopathicum, medicamentum ulcerativae colitis.

Lege plusMitte Inquisitionem
CAS#64887-14-5

CAS#64887-14-5

CAS# 64887-14-5 est medicamento essentialis hypertensionis.

Lege plusMitte Inquisitionem
<...34567...13>
We use cookies to offer you a better browsing experience, analyze site traffic and personalize content. By using this site, you agree to our use of cookies. Privacy Policy
Reject Accept